Welcome To The Haemacure Corporation HUB On AGORACOM

A specialty bio-therapeutics company


New Client Alert!!!

AGORACOM Welcomes TransCanna (TCAN:CSE) Developing The Largest Multi-Purpose Cannabis Facility in California

  • $2M CAD Revenue April 2020
  • $24.6M CAD Revenue Run Rate solely from TransCanna test facility
  • $90M Annual Revenue expected from first full year upon completion of 196,000 Sq Ft Daly facility Q3 2021
  • Daly facility will be one of the largest cannabis facilities in California
  • Recently acquired two California companies,
    • High-end award winning edible producer Soldaze
    • Premium indoor cultivator and distributer Lyfted Farms
  • Lyfted Farms products sold in select Cookies Locations - The most recognizable name in high-end Cannabis.
  • 2019 California Cannabis sales over $3B, industry currently fragmented
  • Direct to dispensary model, cutting out the middleman

Transcanna dark

Hub On AGORACOM / Read Release


Haemacure Corporation Management

Joseph A. Akers,

B.Sc., MBA

Mr. Joseph Akers started his career in the healthcare industry by joining Cutter Laboratories in California in 1970, which later became Bayer AG’s (BAY-NYSE) Biological Products division. Over the years, Mr. Akers held various senior and executive positions in corporate finance and administration at Bayer in Europe and the U.S. In 1999, he was appointed executive vice president and chief administrative and financial officer of Bayer Corporation (the U.S. subsidiary of Bayer AG). In 2004, he was appointed president of Bayer HealthCare’s Hematology/Cardiology business unit, from which he retired in 2007.

Joseph Galli

Chairman and Chief Executive Officer

Mr. Galli is founder and managing partner of PENTOR Alliance Corporation and PENTOR Capital Corp.  Over the past 25 years, Mr. Galli has completed dozens of restructuring, due diligence and acquisition mandates in numerous industries on behalf of several private equity and venture capital firms and industry clients.  He has directed over 200 conferences, seminars and workshops, has been a director of several private and public organizations and is also an investor in a number of early stage public companies.  Prior to forming the PENTOR group of companies, Mr. Galli was a consultant with Ernst & Whinney (now KPMG International) where he successfully raised millions of dollars and gained expertise in insolvency, bankruptcy and corporate restructuring.

Christian Hours, Ph.D.

Vice President, Quality and Technical Affairs

Dr. Christian Hours was director of quality assurance at IAF BioVac Inc., a subsidiary of BioChem Pharma Inc. (now part of Shire plc [SHPGY-NASDAQ]) prior to joining Haemacure. Dr. Hours also has relevant experience in the regulatory process of introducing new biological products to the market, as well as in technology transfers. Before joining the industry, he spent 10 years researching molecular biology and virology. Dr. Hours holds a Master’s in biology and biochemistry from Université Marseilles-Luminy, a Ph.D. in biochemistry from McGill University, and a DSA from HEC Montréal.

Dawn Benson

Director of Quality Assurance and Quality Control

Ms. Dawn Benson has over 10 years of experience in the quality assurance and quality control fields, having held quality assurance positions at biopharmaceuticals, consumer products and plasma fractionation companies. Before joining Haemacure, Ms. Benson was Sr. Manager of Quality Assurance at Jazz Pharmaceuticals. Ms. Benson also has experience with introducing new drug products to market, as well as in technology transfers. Ms. Benson holds a Bachelor’s degree in Chemistry and Biology from the University of North Carolina at Wilmington

Marc Paquin

President and Founder

Mr. Paquin founded Haemacure in 1991.  He was also founder, a director and President and Chief Executive Officer of Autologous Systems, Inc., the first commercial private blood bank in Canada.  Prior to founding Autologous Systems, Inc., Mr. Paquin was Vice-President and General Manager of Syntex Diagnostic (Canada) Inc., where he was responsible for the initial set-up of the Syntex Biomedical division in Canada.  Mr. Paquin is the co-founder of the Canadian Institute of Biotechnology and of the Canada Bio-Industry Council.

Lyne Paré, CA

Director, Finance and Administration

Mrs. Pare is a chartered accountant.  Mrs. Paré’s early career was in public accounting where she worked as an external auditor with a national firm from 1988 to 1994.  Prior to joining Haemacure in August 1996, Mrs. Paré worked for Pillard Combustion, an engineering firm, as Financial and Administrative Controller of the North American subsidiaries of its parent, E.G.C.I. Pillard, a French company.

Gilles Lemieux, B.Com., LL.L.,

Corporate Secretary, Investor Relations

Mr. Gilles Lemieux graduated from HEC Montréal in 1975 with a B. Com. and from Université de Montréal in 1978 with a LL.L. He was called to the Québec Bar in 1979 and began his legal career in 1979 at the Montréal offices of Stikeman Elliott LLP. In October 1981, he joined Ayerst Laboratories (part of Wyeth [WYE-NYSE]) as legal counsel and secretary, and VIA Rail Canada Inc. in 1986 as senior legal counsel, commercial and corporate. Mr. Lemieux has been a sole practitioner since 1994 and was appointed secretary of Haemacure in 1997. He has also been the secretary of three other public companies listed on the TSX. He was president of the Québec chapter of the Canadian Corporate Counsel Association from 1998 to 2002 and a director of the association from 2001 to 2005. He is a member of the Québec Association of Corporate Secretaries and General Counsels.

Last changed at 07-Oct-2008 05:07PM